Siga este enlace para ver otros tipos de publicaciones sobre el tema: Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q).
Artículos de revistas sobre el tema "Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q)"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte los 45 mejores artículos de revistas para su investigación sobre el tema "Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q)".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Explore artículos de revistas sobre una amplia variedad de disciplinas y organice su bibliografía correctamente.
1
Ruggeri, Mirella. "Quality of Life, Enjoyment and Satisfaction Questionnaire (Q-LES-Q)". Epidemiologia e Psichiatria Sociale 16, n.º 1 (marzo de 2007): 79–81. http://dx.doi.org/10.1017/s1121189x00004644.
Texto completo
2
Endicott, Jean, Wilma Harrison y Dianne Schechter. "The Instrument". Epidemiologia e Psichiatria Sociale 16, n.º 1 (marzo de 2007): 88–89. http://dx.doi.org/10.1017/s1121189x00004668.
Texto completo
3
Ibrahim, Mohamad Fadil, Garry Kuan, Hairul Anuar Hashim, Nurul Azuar Hamzah y Yee Cheng Kueh. "Psychometric Properties of the Malay-Language Quality of Life Enjoyment and Satisfaction Scale: A Confirmatory Study on Malaysian Children". International Journal of Environmental Research and Public Health 18, n.º 2 (13 de enero de 2021): 622. http://dx.doi.org/10.3390/ijerph18020622.
Texto completoResumen
The objective of this study was to validate the translated Malay version of the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q-M) scale among Malaysian primary school children using the confirmatory factor analysis (CFA). The Q-LES-Q-M measures the level of enjoyment and satisfaction experienced with relation to physical health, feelings, homework, and leisure. The participants were 607 Malay students, 240 (39.5%) boys and 367 (60.5%) girls, with an age range from 10 to 11 years old. The original version of the Q-LES-Q was translated into the Malay language by forward to backward translation procedures with consideration for the local culture and suitable vocabulary for primary school students. The participants then completed the Q-LES-Q-M. CFA was performed using Mplus 8 software. Using CFA, the initial model did not result in a good data fit. Further analysis of the CFA suggested some changes to the model to improve the fit indices. Model modification included the deletion of three problematic items and co-varying some error items. This resulted in improved fit indices and 40 items remained in the final model. The final model showed good reliability based on two indicators of composite reliability (CR) and Cronbach’s alpha (CA). The factors with their CR and CA were physical activity (CR = 0.857, CA = 0.854), feelings (CR = 0.808, CA = 0.813), homework (CR = 0.837, CA = 0.837) and leisure (CR = 0.742, CA = 0.737). The final measurement consists of 40 items. The retained items were deemed suitable for Malay primary school children. The revised Q-LES-Q-M with 40 items is suitable for measuring the levels of children’s involvement in determining the enjoyment and satisfaction of learning and physical activity.
4
Goracci, Arianna, Mirko Martinucci, Anastassia Kaperoni, Andrea Fagiolini, Chiara Sbaragli, Eleonora Corsi y Paolo Castrogiovanni. "Quality of life and subthreshold obsessive-compulsive disorder". Acta Neuropsychiatrica 19, n.º 6 (diciembre de 2007): 357–61. http://dx.doi.org/10.1111/j.1601-5215.2007.00257.x.
Texto completoResumen
Objective:This study investigates the relationship between subthreshold obsessive-compulsive disorder (OCD) and quality of life (QoL) in a sample from the Italian general population.Methods:A sample of 202 psychiatrically healthy (defined as absence of current axis I and axis II disorders) subjects was recruited by word of mouth from the residential population in the Siena, Salerno and Milano municipalities (Italy). All study subjects completed the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) and the Questionnaire for Obsessive-Compulsive Spectrum (OBS-SR), which explore a wide array of threshold and subthreshold OCD symptoms, behaviours and traits. A diagnostic assessment was conducted to exclude the presence of DSM-IV axis I and axis II disorders using the Mini International Neuropsychiatric Interview and the Structured Clinical Interview for DSM-III-R personality disorders, respectively.Results:A statistically significant correlation was found between the OBS-SR total score and the Q-LES-Q domains of physical health, subjective feelings, work, school, social relationships and general activities. There was also a statistically significant correlation between several Q-LES-Q and OBS-SR domains.Conclusions:The presence of subthreshold OCD is correlated with poorer QoL. More research is needed to evaluate if specific therapeutic interventions targeting subthreshold obsessive-compulsive symptoms can lead to a significant improvement in the QoL of the affected individuals.
5
ENDICOTT, JEAN, JOHN NEE, RUOYONG YANG y CHRISTOPHER WOHLBERG. "Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q): Reliability and Validity". Journal of the American Academy of Child & Adolescent Psychiatry 45, n.º 4 (abril de 2006): 401–7. http://dx.doi.org/10.1097/01.chi.0000198590.38325.81.
Texto completo
6
Mear, I., K. Conway, L. Touzet, J. Endicott y M. O'Leary. "PMD42 LINGUISTIC VALIDATION OF THE QUALITY OF LIFE ENJOYMENT AND SATISFACTION QUESTIONNAIRE (Q-LES-Q) IN 24 LANGUAGES". Value in Health 6, n.º 6 (noviembre de 2003): 807. http://dx.doi.org/10.1016/s1098-3015(10)62053-0.
Texto completo
7
Pompili, M., G. Paolo y P. Martelletti. "EV435Life satisfaction and enjoyment in medication-overuse headache patients: The role of depression and insomnia". European Psychiatry 33, S1 (marzo de 2016): S395. http://dx.doi.org/10.1016/j.eurpsy.2016.01.1420.
Texto completoResumen
IntroductionEpidemiological research has documented a strong association between medication-overuse headache (MOH)and psychiatric disorders, emotional disturbances, and disordered personality traits, which are associated with worse outcomes, poorer quality of life, and higher costs to the health care system.ObjectivesIdentifying risk factors for progression of headache into MOH represents one of the most relevant public health priorities and psychiatric comorbidity has been identified as a potential factor related to chronic phases.AimsThe aim of the present study was to determine whether depression and insomnia complaints were associated with satisfaction and enjoyment with one's own life in Medication-overuse headache (MOH) patients, and whether insomnia complaints were able to explain part of the variance of QoL explained by depression.MethodsParticipants were 187 consecutive adult outpatients admitted to the outpatient headache clinic. Patients were administered the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q), the Beck Depression Inventory–II (BDI-II), and the Athens Insomnia Scale (AIS).ResultsThe BDI was associated with all the dimensions of the Q-LES-Q, with more severe depression being associated independently with lower satisfaction and enjoyment with one's own life. The AIS was independently and significantly associated only with physical health, such that patients with more insomnia complaints were 3.1 times (P < 0.001) more likely to report lower physical health satisfaction.ConclusionsOur findings confirmed that MOH has a negative impact on quality of life, and suggested that depression and insomnia were independently associated with satisfaction and enjoyment of life in MOH patients.Disclosure of interestThe authors have not supplied their declaration of competing interest.
8
Zaboski, Brian A., Alexandra Gilbert, Rebecca Hamblin, Jessica Andrews, Amaya Ramos, Joshua M. Nadeau y Eric A. Storch. "Quality of life in children and adolescents with obsessive-compulsive disorder: The Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q)". Bulletin of the Menninger Clinic 83, n.º 4 (diciembre de 2019): 377–97. http://dx.doi.org/10.1521/bumc_2019_83_03.
Texto completoResumen
The current study examined quality of life (QOL) and its clinical correlates among 225 intensive treatment-seeking children and adolescents with obsessive-compulsive disorder (OCD) using the Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q). Youth completed the PQ-LES-Q along with self-report measures assessing functional impairment, anxiety sensitivity, OCD symptoms, nonspecific anxiety, depression, and social anxiety. Parents completed measures on their child's anxiety, the presence of inattention/hyperactivity, depression, functional impairment, and frequency of family accommodation of symptoms. Contrary to expectation, child-reported OCD symptoms did not significantly predict QOL; however, lower overall QOL was strongly associated with the presence of comorbid major depressive disorder (g=3D −0.76) and slightly related to comorbid social phobia (g=3D −0.36). These results suggest that assessing and addressing comorbid conditions in the treatment of youth with OCD is an important component of intensive treatment.
9
Stevanovic, Dejan. "Is the Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) a unidimensional or bidimensional instrument?" Quality of Life Research 23, n.º 4 (22 de noviembre de 2013): 1299–300. http://dx.doi.org/10.1007/s11136-013-0566-7.
Texto completo
10
Michalak, Erin E., Lakshmi N. Yatham, Dante DC Wan y Raymond W. Lam. "Perceived Quality of Life in Patients with Bipolar Disorder. Does Group Psychoeducation Have an Impact?" Canadian Journal of Psychiatry 50, n.º 2 (febrero de 2005): 95–100. http://dx.doi.org/10.1177/070674370505000204.
Texto completoResumen
Objective: A large body of research has now accumulated concerning quality of life (QoL) for patients with major depressive disorder, both in terms of describing levels of well-being and in terms of assessing the impact of treatment interventions. However, there is little information concerning QoL for patients with bipolar disorder (BD), and there is relatively little published evidence concerning the effectiveness of psychological interventions for BD. We aimed to assess the impact of a time-limited psychoeducation (PE) group therapy upon perceived QoL among patients with BD. Method: Participants were patients ( n = 57) with BD type I or II who were clinically described as euthymic or mildly symptomatic. Treatment intervention was a standardized, 8-week group PE course delivered in a mood disorders program in British Columbia, Canada. Using retrospective chart review and the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q), we assessed QoL at baseline and at 8 weeks. Results: Mean baseline Q-LES-Q scores were 56%, representing moderate impairment in QoL. Group PE was associated with a 5-point increase in Q-LES-Q scores (where higher scores indicate better QoL). Examination of the questionnaire's subscales revealed that 2 domains (that is, physical functioning and general satisfaction) increased significantly following PE, with the remaining domains showing nonsignificant trends toward improved functioning. Multivariate analysis indicated that only one factor (having had a recent episode of depression) significantly predicted pre- and posttreatment Q-LES-Q scores. Conclusion: Patients with BD continue to show impaired QoL even when clinically euthymic. Although preliminary, our results show that group PE is associated with improved QoL in this population, both in terms of general satisfaction and in relation to levels of physical functioning. The use of PE as an adjunct to pharmacotherapy in BD should be further studied with particular emphasis on characterizing the effects of treatment intervention on perceived QoL.
11
Albasheer, Osama B. "The Impact of Depressive Symptoms on the Quality of Life of Patients with Type 2 Diabetes in Jazan Region, KSA". Current Diabetes Reviews 15, n.º 4 (11 de junio de 2019): 288–93. http://dx.doi.org/10.2174/1573399814666181002100223.
Texto completoResumen
Background: The purpose of this study is to determine the impact of depressive symptoms on the quality of life of type 2 diabetic patients (T2DM). Methods: A cross-sectional study of 332 T2DM patients aged ≥18 years living in Jazan region of Saudi Arabia was conducted. Validated questionnaire was used for demographic and disease characteristics. Depressive symptoms of the participants were assessed using the Patient Health Questionnaire (PHQ-9). The Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF) was utilized to assess the degree of life enjoyment and satisfaction. Results: Depressive symptoms were observed in 34.7% (112) of the total participants. The overall sense of wellbeing (mean 3.23, P. value 0.000), physical (mean 3.37, P. value 0.003), psychosocial (mean 2.99 P. value 0.000) and social domains (mean 3.53, P. value 0.000) of quality of life were significantly reduced in T2DM patients with depressive symptoms. Conclusion: The impact of depressive symptoms on quality of life of T2DM patients was more significant than the impact of diabetes alone. Symptoms of depression reduce the individual coping and hence reduce functioning. This study emphasizes the vital importance of an integrated holistic approach that addresses both the practical and emotional issues in diabetes care.
12
Ritsner, Michael, Rena Kurs, Anatoly Gibel, Yael Ratner y Jean Endicott. "Validity of an abbreviated Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q-18) for schizophrenia, schizoaffective,and mood disorder patients". Quality of Life Research 14, n.º 7 (septiembre de 2005): 1693–703. http://dx.doi.org/10.1007/s11136-005-2816-9.
Texto completo
13
Matthies, Swantje, Chiharu Sadohara-Bannwarth, Sebastian Lehnhart, Jan Schulte-Maeter y Alexandra Philipsen. "The Impact of Depressive Symptoms and Traumatic Experiences on Quality of Life in Adults With ADHD". Journal of Attention Disorders 22, n.º 5 (2 de septiembre de 2016): 486–96. http://dx.doi.org/10.1177/1087054716654568.
Texto completoResumen
Objective: We assessed factors influencing quality of life (QoL) in adults with ADHD. Method: QoL, traumatic childhood experiences, and depression were assessed using the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q), Childhood Trauma Questionnaire (CTQ), and Beck Depression Inventory (BDI), respectively, in 60 adult ADHD outpatients and 60 age- and gender-matched controls. Results: Emotional neglect or abuse had occurred significantly more often during childhood in adults with ADHD. Depressive symptoms were rated significantly higher by ADHD patients. QoL was significantly lower in adults with ADHD, and the variables depression, ADHD symptom severity, and traumatic load, accounted for ~60% of variance in overall QoL. Conclusion: QoL is significantly reduced in adult ADHD patients. Depressive symptoms and traumatic childhood experiences influence QoL. Treatment for adult ADHD patients should take the high interdependence of depressive symptoms, childhood trauma, and QoL into consideration.
14
Vrbova, K., J. Prasko, D. Jelenova, A. Kovacsova, K. Latalova y Z. Sigmundova. "The quality of life of patients suffering from schizophrenia - a comparison with healthy controls". European Psychiatry 26, S2 (marzo de 2011): 1525. http://dx.doi.org/10.1016/s0924-9338(11)73229-1.
Texto completoResumen
BackgroundIn the past, the first goal of schizophrenia treatment was to reduce psychotic symptoms, mainly positive symptoms. Recently, as a result of an emphasis on patient needs, the concept of quality of life (QoL) has been brought into the treatment. The goal has therefore changed from the alleviation of symptoms to improvement of the patient's satisfaction with social activities. Self-evaluations by people with schizophrenia were previously thought to lack reliability because of the presence of psychopathological symptoms and poor awareness of the disease. Recently the importance of evaluating the satisfaction of patients themselves, however, has been recognized in schizophrenia. Studies on this field showed us, that QoL data from patients with chronic mental illness were reliable and concluded that subjective QoL evaluation was applicable to such patients.AimsThe purpose of the present study was to compare the QoL in patients suffering from schizophrenia in clinical remission with healthy controls and examine the extent of the effects of subjective cognitive functioning on QoL in these patients.MethodsData were obtained using the quality of life questionnaire (Quality of Life Enjoyment and Satisfaction - Q-LES-Q), and subjective questionnaire for cognitive dysfunction (Cognitive Failures Questionnaire - CFQ) for 40 schizophrenia patients in clinical remission and 40 healthy controls.ResultsCognitive function correlates negatively with subjective QoL in patients with schizophrenia.
15
Čuček Trifkovič, Klavdija, Blanka Kores Plesničar, Alenka Kobolt, Margaret Denny, Suzanne Denieffe y Leona Cilar. "Quality of life of alcohol-dependent adults". Obzornik zdravstvene nege 54, n.º 3 (21 de septiembre de 2020): 204–13. http://dx.doi.org/10.14528/snr.2020.54.3.2985.
Texto completoResumen
Introduction: Alcohol dependence is the most prevalent addiction disorder that develops gradually as an interplay of individual and social factors. It impacts the quality of life of affected individuals. The purpose of this study was to examine the quality of life of alcohol-dependent people at different stages of treatment compared to individuals without alcohol dependence.Methods: A mixed-methods study was conducted. First, a cross-sectional study (n = 502) was conducted using a validated Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q). Focus groups for subjective quality of life assessment were also conducted. Data were analysed using descriptive and inference methods (Mann Whitney U Test) with the SPSS, version 20 programme.Results: Non-dependent participants are significantly more satisfied with each of the quality of life component than alcohol-dependent participants. Differences were demonstrated in a sense of well-being and leisure-time activities. Differences between alcohol-dependent and non-dependent participants were seen in the domains of physical health, work satisfaction and social relationships.Discussion and conclusion: Alcohol-dependent participants reported a lower quality of life than non-alcohol dependent participants as alcohol dependents confront numerous problems associated with their dependence. There is a need for further research in the field of alcohol dependence in relation to the quality of life.
16
Mychaskiw, M. A., J. M. Alvir, D. L. Hoffman, B. K. Herman y A. Joshi. "Functional and Quality of Life Impairment in Generalized Anxiety Disorder: Effect of Short-term Treatment with Pregabalin and Venlafaxine-XR". European Psychiatry 24, S1 (enero de 2009): 1. http://dx.doi.org/10.1016/s0924-9338(09)70768-0.
Texto completoResumen
Aims:To determine the incidence and clinical correlates of functional and quality of life (QoL) impairment in patients with generalized anxiety disorder (GAD), and to evaluate the efficacy of pregabalin and venlafaxine-XR in improving functional outcomes.Methods:A double-blind trial in adults who met DSM-IV criteria for GAD, with a HAM-A total score ≥20, randomized to 8-weeks of flexible-dose treatment with pregabalin (300-600 mg/d, N=121), venlafaxine-XR(75-225 mg/d, N=125), or placebo (N=128). Anxiety-related impairment in QoL was evaluated using the Quality of Life, Enjoyment, and Satisfaction Questionnaire (Q-LES-Q) and impairment in functioning using the Sheehan Disability Scale (SDS).Results:At baseline, a similar proportion of patients in the 3 treatment groups met criteria for impairment on the Q-LES-Q (70.1%-77.6%) and SDS (74.1%-82.7%). For all groups combined, baseline impairment was more highly correlated with psychic than somatic anxiety on both the Q-LES-Q and SDS (Spearman r-values, -0.32 vs. -0.28 and 0.27 vs. 0.14,respectively). On the SDS but not on the Q-LES-Q, significantly more subjects in the pregabalin (67.2%) and venlafaxine-XR (59.5%) groups had improvement into the normative range compared with placebo (42.9%; p< 0.05) at endpoint. The mean HAM-A change score (all subjects) was significantly greater among patients whose Q-LES-Q returned to normal (“remitters” vs. non-remitters: -19.3 vs. -11.9; p< 0.05).Conclusion:At baseline, approximately 75% of GAD patients reported moderate-to-severe impairment in QoL and functioning which was modestly correlated with severity of GAD symptomatology. Pregabalin produced improvement in QoL and functioning that was correlated with reduction in anxiety symptom severity.
17
Lee, Yun-Tse, Shen-Ing Liu, Hui-Chun Huang, Fang-Ju Sun, Chiu-Ron Huang y Albert Yeung. "Validity and reliability of the Chinese version of the Short Form of Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q-SF)". Quality of Life Research 23, n.º 3 (24 de septiembre de 2013): 907–16. http://dx.doi.org/10.1007/s11136-013-0528-0.
Texto completo
18
Michalak, Erin E., Edwin M. Tam, CV Manjunath, Anthony J. Levitt, Robert D. Levitan y Raymond W. Lam. "Quality of Life in Patients with Seasonal Affective Disorder: Summer vs Winter Scores". Canadian Journal of Psychiatry 50, n.º 5 (abril de 2005): 292–95. http://dx.doi.org/10.1177/070674370505000510.
Texto completoResumen
Objective: To compare perceived quality of life (QoL) in patients diagnosed with seasonal affective disorder (SAD) during the winter and summer months. Methods: Twenty-six patients who were enrolled in an ongoing multicentre study in Canada completed 2 measures of QoL (the 20-item Medical Outcomes Study Short-Form General Health Survey [SF-20] and the Quality of Life Enjoyment and Satisfaction Questionnaire, [Q-LES-Q]) during the winter, when suffering from depression, and again during the summer months. Results: Both general and health-related QoL scores were significantly improved in patients with SAD during the summer months, with scores for the most part falling within normal range. Conclusions: Perceived QoL in patients with SAD is markedly impaired during the winter months but shows a substantial rebound during the summer months. The findings of this study provide further evidence that SAD is a distinct diagnostic entity.
19
Voicehovskis, Vladimirs V., Gunta Ancane, Julija Voicehovska y Andrejs Skesters. "The quality of life enjoyment and satisfaction questionnaire (Q-LES-Q), Latvian language version: Study, validation, and quality of life measurement in posttraumatic stress disorder risk patients". International Journal of Psychophysiology 77, n.º 3 (septiembre de 2010): 276–77. http://dx.doi.org/10.1016/j.ijpsycho.2010.06.128.
Texto completo
20
Mento, Carmela, Basilia Piraino, Amelia Rizzo, Roberta Vento, Luciana Rigoli, Emanuela Moschella, Carmelo Salpietro y Salvatore Settineri. "Affective control and life satisfaction in thalassemics". International Journal of Psychological Research 8, n.º 1 (1 de enero de 2015): 91–98. http://dx.doi.org/10.21500/20112084.648.
Texto completoResumen
Background. Thalassemia is a chronic disease that can lead to an impact on psychological functioning and social behavior of patients. However, still little is known about the specific psychological aspects of the disease, such as the degree of tension, life satisfaction and affective control, especially in adult patients.Aim. The purpose of this study is to investigate whether patients with thalassemia have specific psychological pattern relating to the dimensions of tension, satisfaction and quality of life, management of affection.Method. We evaluated 31 patients with thalassemia major and intermedia (19 women and 12 men) aged between 18 and 50 years (M = 34 + 16), belonging to the Complex Unit of Medical Genetics. For the evaluation were used the Profile of Mood States (POMS), the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) and the Rorschach test.Results. The findings show an inverse relationship between the levels of self-reported tension and the affective control indicators at Rorschach. Life satisfaction, instead, seems to vary according to the severity of the disease - major vs. intermediate - and the type of therapy.Conclusions. An understanding of the psychological mechanisms involved in thalassemia, both self-reported and projective, can contribute to a wider patient take-over, by considering the subjective aspects related to the psychological and socio-emotional well-being, fundamental in the care compliance.
21
Chatterjee, Seshadri Sekhar, Sayantanava Mitra, Prathama Guha y Kaustav Chakraborty. "Prevalence of restless legs syndrome in somatoform pain disorder and its effect on quality of life". Journal of Neurosciences in Rural Practice 6, n.º 02 (febrero de 2015): 160–64. http://dx.doi.org/10.4103/0976-3147.153219.
Texto completoResumen
ABSTRACT Background: Persistent somatoform pain disorder (SPD) is a condition in which the patient suffers from persistent, severe and distressing pain; and from associated physical and psychological distress. While presence of restless leg syndrome (RLS) in SPD is understudied, their association might have an impact on general well-being and quality of life (QoL) in SPD. Aims and Objectives: Present study aimed at evaluating the prevalence of RLS in SPD patients attending outpatient department services at a tertiary care institute in eastern India. Materials and Methods: Two hundred and forty consecutive patients with SPD were screened initially and after applying appropriate inclusion and exclusion criteria, 192 subjects (male = 85, female = 107) were included in the study. Severity of RLS was assessed using a questionnaire of the International Restless Legs Syndrome Study Group and QoL was measured on QoL Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF). Results: Revealed a 28% prevalence of RLS is in patients with SPD, which is much higher than its estimated population prevalence. A larger proportion of those with RLS had continuous course of SPD, longer duration of SPD, and higher daytime sleepiness. They also had poorer scores on Q-LES-Q-SF, indicating a poorer QoL overall. Discussion and Conclusion: This is the first report, to the best of our knowledge, on this aspect from India. While this association between RLS and SPD may have biological explanation based on abnormal monoaminergic neurotransmission system, the findings call for more vigilant approach to SPD patients in order to improve their QoL and add to their well-being.
22
McEvoy, Joseph, Benjamin Carroll, Sanjay Gandhi, Avery Rizio, Stephen Maher, Mark Kosinski y Jakob Bjorner. "143 Effect of Tardive Dyskinesia on Quality of Life: Patient-Reported Symptom Severity Is Associated With Deficits in Physical, Mental, and Social Functioning". CNS Spectrums 23, n.º 1 (febrero de 2018): 89. http://dx.doi.org/10.1017/s109285291800038x.
Texto completoResumen
AbstractIntroductionTardive dyskinesia (TD), an often-irreversible movement disorder typically caused by exposure to antipsychotics, most commonly affects the face, mouth, and tongue and may be debilitatingObjectiveTo investigate TD burden on patients’ quality of life and functionalityMethodsAdults with clinician-confirmed schizophrenia, bipolar disorder, or major depressive disorder participated in an observational study. Approximately half (47%) ofparticipants had a clinician-confirmed TD diagnosis. Participants completed the SF-12v2 Health Survey® (SF-12v2), Quality of Life Enjoyment and Satisfaction Questionnaire Short Form (Q-LES-Q-SF), social withdrawal subscale of the Internalized Stigma of Mental Illness scale (SW-ISMI), and rated the severity of their TD symptoms. Group differences in SF-12v2 physical and mental component summaries (PCS and MCS), Q-LES-Q-SF, and SW-ISMI scores were analyzed.ResultsTD (n=79) and non-TD (n=90) groups were similar in age, gender, and number of patients with schizophrenia, bipolar disorder, and major depressive disorder. TD patients reported significantly worse scores on PCS (P=0.003), Q-LES-Q-SF (P<0.001) and SW-ISMI (P<0.001) than non-TD patients. The difference in PCS exceeded the established minimal clinically important difference (MCID) of 3 points. When stratified by TD severity, those with more severe symptoms had significantly worse Q-LES-Q-SF (P<0.001) and SW-ISMI (P=0.006) scores than those with less severe symptoms. Differences in PCS (P=0.12) and MCS (P=0.89) were in the expected direction and exceeded the MCID.ConclusionsAmong patients with psychiatric disorders, TD is associated with significant physical health burden and incremental mental health burden. TD severity is also associated with lower overall quality of life and greater social withdrawal.Presented at: Psych Congress; September 16–19, 2017; New Orleans, Louisiana, USA.Funding AcknowledgementsThis study was funded by Teva Pharmaceutical Industries, Petach Tikva, Israel.
23
Latalova, K., T. Diveky, D. Kamaradova, H. Velartova y J. Prasko. "The quality of life of patients suffering from bipolar disorder – a comparison with schizophrenic patients and healthy controls". European Psychiatry 26, S2 (marzo de 2011): 221. http://dx.doi.org/10.1016/s0924-9338(11)71931-9.
Texto completoResumen
Host of studies have now examined QoL in patients with major depressive disorder and schizophrenia until recently few had specifically focused upon QoL in patients with bipolar disorder. The purpose of the present study was to find out the QoL data in patients suffering from bipolar disorder in clinical remission and examine the extent of the effects of the demographical and clinical data on QoL in these patients. The second aim was to compare the QoL data with the data of patients suffering from schizophrenia in clinical remission and with healthy controls.Data were obtained by using the quality of life questionnaire (Quality of Life Enjoyment and Satisfaction - Q-LES-Q) for 41 bipolar patients in clinical remission. The data of these subjects were compared with the data of 40 schizophrenic patients in clinical remission and with 40 healthy controls.There are statistically significant difference in comparison with schizophrenic patients, but not in comparison with healthy controls. There were higher mean scores in most Q-LES-Q summary scales in patients with bipolar disorder in comparison with schizophrenic patients and in some summary scales in comparison with healthy controls.Our results suggest the same or higher subjective quality of life in patients suffering with bipolar disorder in clinical remission in comparison with healthy controls and higher subjective quality of life in bipolar patients in clinical remission in comparison with schizophrenic patients in clinical remission.Supported by grant IGA MZ ČR NT11047
24
Gustafsson, U. y L. Fajutrao. "FC22-02 - Effect of quetiapine on functioning and quality of life in bipolar depression". European Psychiatry 26, S2 (marzo de 2011): 1935. http://dx.doi.org/10.1016/s0924-9338(11)73639-2.
Texto completoResumen
IntroductionDepression symptoms in bipolar disorder have debilitating effects on functioning and quality of life (QoL).ObjectivesTo assess effects of 8 weeks of quetiapine monotherapy on functioning and QoL in patients with bipolar depression (BPD).AimsTo evaluate functioning and QoL using patient-reported outcomes.MethodsData from 4 trials (BOLDER I and II; EMBOLDEN I and II) of quetiapine (300 and 600 mg/day) in BPD were combined (n = 2593). The Sheehan Disability Scale (SDS) measured functioning (BOLDER II; EMBOLDEN I and II) and the QoL Enjoyment and Satisfaction Questionnaire (Q-LES-Q)-Short Form measured QoL (BOLDER I and II; EMBOLDEN II).ResultsQuetiapine improved overall functioning (mean change [SE] in SDS total score: -7.23 [0.49], -7.49 [0.49], with quetiapine 300 mg/day and quetiapine 600 mg/day, respectively vs placebo (-5.91 [0.54]); P < 0.01 for both). Both doses improved functioning in SDS domains of work/school, social life, and family life/home responsibilities vs placebo (P < 0.05). Quetiapine 600 mg/day reduced days missed from work/school and productivity losses vs placebo (P < 0.01). QoL was improved with both quetiapine doses vs placebo (P < 0.001; least squares mean changes (SE) in Q-LES-Q total score from baseline to Day 57: 9.69 (0.51), 9.95 (0.50), and 6.81 (0.54) with quetiapine 300 mg/day, quetiapine 600 mg/day, and placebo, respectively). Tolerability was consistent with the known safety profile of quetiapine.ConclusionsQuetiapine treatment (300 and 600 mg/day) for 8 weeks significantly improved functioning and QoL vs placebo in patients with BPD.Supported by funding from AstraZeneca Pharmaceuticals LP.
25
Ganesan, Suganya, Nitya Selvaraj, Vinoth Krishna Dass, Nalinidevi Jayabalan, Meher Ali Rajamohammad y Isshwariya Anandan. "Assessment of drug attitude, medication adherence and quality of life among psychiatric patients in South Indian population: a cross sectional study". International Journal of Basic & Clinical Pharmacology 8, n.º 1 (24 de diciembre de 2018): 61. http://dx.doi.org/10.18203/2319-2003.ijbcp20185159.
Texto completoResumen
Background: In spite of many progresses in treatment of psychiatric disorders, medication nonadherence plays an important role in worsening of clinical condition and affects quality of life among psychiatric patients. There are numerous factors contributing for medication nonadherence among patients with mental illness. So, this study was conducted to assess psychiatric patients’ adherence of medication and to improve their quality of life with psychiatric disorder. The objectives of the study were to analyze impact of pharmacophilia and pharmacophobia on medication adherence among patients with psychiatric disorders at a tertiary care hospital and to assess quality of life among pharmacophilic and pharmacophobic patients.Methods: A cross-sectional study was conducted in outpatient psychiatric department for a period of two months. After obtaining informed voluntary consent, patient’s socio-demographic details, diagnosis, and treatment were recorded from prescription slip. Patients above 18yr age with psychiatric diagnosis as per International Classification of Diseases 10 (ICD-10) and receiving at least one psychotropic medication for >1 month were enrolled in study and assessed using: Drug attitude inventory classification (DAI-10); Medication Rating Scale (MARS); Quality of life enjoyment and satisfaction Questionnaire-Short Form (Q-LES-Q-SF).Results: Among 130 patients, 116 were pharmacophilic and 14 were pharmacophobic as per DAI-10 scale. 81.9% of pharmacophilic were adherent to prescribed medication assessed using MARS scale only 14.3% were pharmacophobic. The quality of life was better in pharmacophilic compared to pharmacophobic group (p=0.002) using Q-LES-Q-SF.Conclusions: This study concluded that pharmacophilic patients have higher adherence and good quality of life index compared to pharmacophobic. Proper counselling of pharmacophobic patients by psychiatrists could improve adherence and QOL.
26
Buitelaar, J. K., M. Casas, A. Philipsen, J. J. S. Kooij, J. A. Ramos-Quiroga, J. Dejonckheere, J. C. van Oene y B. Schäuble. "Functional improvement and correlations with symptomatic improvement in adults with attention deficit hyperactivity disorder receiving long-acting methylphenidate". Psychological Medicine 42, n.º 1 (1 de junio de 2011): 195–204. http://dx.doi.org/10.1017/s0033291711000845.
Texto completoResumen
BackgroundData on the relationship between core symptoms and daily functioning in adults with attention deficit hyperactivity disorder (ADHD) are limited. Daily functioning was assessed as part of an open-label extension, and associations with symptom scores were evaluated.MethodAfter a 5-week double-blind study with adults with ADHD receiving osmotic-controlled release oral delivery system (OROS) methylphenidate (MPH) 18, 36 or 72 mg/day, or placebo, participants were eligible for a 7-week open-label extension in which all patients received OROS MPH. Data for the Conners' Adult ADHD Rating Scale – Observer: Screening Version (CAARS-O:SV) (primary endpoint) have been presented previously. Secondary endpoints included the observer self-reported short version of the CAARS (CAARS-S:S) and the Clinical Global Impressions – Severity Scale (CGI-S). Daily functioning and quality of life were assessed using the Sheehan Disability Scale (SDS) and the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) respectively. In post-hoc analyses, changes in CAARS-O:SV were evaluated in subgroups. Relationships between symptom and functional outcomes were evaluated in a multivariate regression analysis.ResultsA total of 370 patients entered the open-label extension. Significant improvements from baseline in CAARS-O:SV were similar regardless of sex, ADHD subtype, prior treatment or psychiatric co-morbidity. Significant improvements from double-blind baseline were also seen for the CAARS-S:S, CGI-S, SDS and Q-LES-Q. Improvements in the CAARS-O:SV Hyperactivity/Impulsivity subscale were associated with improvements in SDS total and subscale scores, and in the Q-LES-Q score at open-label endpoint. Improvements in CAARS-O:SV Inattention subscale and CGI-S scores were not significantly associated with functional changes.ConclusionsImprovements in ADHD symptoms relating to hyperactivity and impulsivity in adults receiving OROS MPH are associated with improvements in daily functioning and quality of life.
27
Enatescu, V. R., I. Papava, R. S. Romosan, A. Grozavu, V. Enatescu, I. Enatescu y L. Diaconu. "The impact of type D personality on the quality of life and on microangiopathic and macroangiopathic complications in outpatients with type 2 diabetes mellitus". European Psychiatry 41, S1 (abril de 2017): S491—S492. http://dx.doi.org/10.1016/j.eurpsy.2017.01.600.
Texto completoResumen
IntroductionIn 2015, the worldwide point prevalence for diabetes mellitus was 8.8%. Type D personality was found as being more prevalent in type 2 diabetes than in the general population.ObjectivesWe aimed to reveal the frequency of type D personality and to analyze the impact of type D personality on both quality of life and angiopathic complications, in patients with type 2 diabetes from our region.MethodsA cross-sectional research was performed on 79 outpatients that were monitored for diabetes mellitus at Timisoara diabetes, nutrition and metabolic diseases clinic. Type D personality was assessed with the DS-14 scale. Quality of life was quantified by using the Q-LES-Q-SF scale (Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form). The angiopathic complications were abstracted from medical records.ResultsType D personality was present in 38 subjects with diabetes mellitus (48.10%). Compared to those without type D personality, patients with type D personality and diabetes had significant lower mean scores for the following domains of the Q-LES-Q-SF scale: social relationships (P < 0.001), daily life function (P = 0.027), sexual activity (P = 0.005), to get around physically (P < 0.001), work or hobbies (P = 0.008) and raw score (P = 0.003). Type D personality did not make any difference regarding micro and macroangiopathic complications of type 2 diabetes patients.ConclusionsType D personality, a highly frequent entity, did not make the difference with respect to diabetic complications; however, it may interfere significantly with several facets of the quality of life of these patients. These results should be taken into account for an interdisciplinary approach to these patients.Disclosure of interestThe authors have not supplied their declaration of competing interest.
28
Ramaswamy, Sriram, Jayakrishna Madabushi, John Hunziker, Subhash C. Bhatia y Frederick Petty. "An Open-Label Trial of Memantine for Cognitive Impairment in Patients with Posttraumatic Stress Disorder". Journal of Aging Research 2015 (2015): 1–6. http://dx.doi.org/10.1155/2015/934162.
Texto completoResumen
Background. Studies using standard neuropsychological instruments have demonstrated memory deficits in patients with PTSD. We evaluated the efficacy and safety of the N-methyl-D-aspartate antagonist memantine in veterans with PTSD and cognitive impairment.Methods. Twenty-six veterans with PTSD and cognitive impairment received 16 weeks of memantine in an open-label fashion. Cognition was assessed using the Spatial Span, Logical Memory I, and Letter-Number Sequencing subtests of the Wechsler Memory Scale III and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). RBANS measures attention, language, visuospatial skills, and immediate and delayed memories. The Clinician Administered PTSD Scale (CAPS), Hamilton Depression Scale (HAM-D), Hamilton Anxiety Scale (HAM-A), Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q), and Sheehan Disability Scale (SDS) were secondary outcome measures.Results. There was a significant improvement in RBANS, both total and subscale scores (P<0.05), over time. There was a reduction in total CAPS scores, avoidance/numbing symptoms (CAPS-C) and hyperarousal symptoms (CAPS-D), HAM-D, Q-LES-Q, and SDS scores. However, there was no reduction in reexperiencing (CAPS-B) and HAM-A scores. Memantine was well tolerated.Conclusions.Memantine improved cognitive symptoms, PTSD symptoms, and mood in veterans with PTSD. Randomized double-blind studies are needed to validate these preliminary observations.
29
Holubova, M., J. Prasko, M. Ociskova, M. Marackova, A. Grambal y M. Slepecky. "Self-stigma and quality of life in outpatients with depressive disorder – a cross-sectional study". European Psychiatry 41, S1 (abril de 2017): S238. http://dx.doi.org/10.1016/j.eurpsy.2017.02.003.
Texto completoResumen
BackgroundSelf-stigma is a maladaptive psychosocial phenomenon that may disturb many areas of patient's life and have the negative impact on their quality of life. The present study explored the association between self-stigma, quality of life, demographic data, and the severity of symptoms in patients with depressive disorder.MethodPatients, who met ICD-10 research criteria for depressive disorder, were enrolled in the cross-sectional study. All probands completed these measurements: the Quality of Life Satisfaction and Enjoyment Questionnaire (Q-LES-Q), the Internalised Stigma of Mental Illness Scale (ISMI), demographic questionnaire, and the severity of the disorder measured by objective and subjective Clinical Global Impression severity scales (CGI).ResultsEighty-one depressive patients (with persistent affective disorder – dysthymia, major depressive disorder or recurrent depressive disorder) and 43 healthy controls contributed to the study. Comparing with the healthy control group, there was a lower quality of life in patients with depression. The level of self-stigma correlated positively with total symptom severity score and negatively with the quality of life. Multiple regression analysis discovered that the overall rating of objective symptoms severity and self-stigma were significantly associated with the quality of life.ConclusionsPresent study suggests the lower quality of life in outpatients with depressive disorder in comparison with healthy controls, and the negative impact of self-stigma level on quality of life in patients suffering from depressive disorders.Disclosure of interestThe authors have not supplied their declaration of competing interest.
30
Holubova, M. y J. Prasko. "Connection Between Coping Strategies and Quality of Life in Outpatient with Depression – Cross-sectional Study". European Psychiatry 41, S1 (abril de 2017): s239. http://dx.doi.org/10.1016/j.eurpsy.2017.02.004.
Texto completoResumen
BackgroundThe quality of life is a multidimensional phenomenon which represents all aspects of patient's well-being and various areas of the patient's life. Specific coping strategies may be connected with the quality of life and also with the severity of the disorder. The objective of this study was to explore the relationship between the coping strategies and quality of life in outpatients with depressive disorder.MethodsEighty-two outpatients, who met ICD-10 criteria for depressive disorders, were enrolled in the cross-sectional study. Data on sociodemographic and clinical variables were recorded. Individuals with depression filled out the standardized measures: The Stress Coping Style Questionnaire (SVF-78), The Quality of Life Satisfaction and Enjoyment Questionnaire (Q-LES-Q), and The Clinical Global Impression (CGI).ResultsThe patients overuse negative coping strategies, especially, escape tendency and resignation. Using of positive coping is in average level (the strategy Positive self-instruction is little used). Coping strategies are significantly associated with quality of life. Higher using of positive coping has a positive association with QoL. The main factors related to QoL are the subjective severity of the disorder, employment and positive coping strategies according to regression analysis.ConclusionsThis study revealed the connection between coping strategies and quality of life in patients with depressive disorders. Strengthening the use of positive coping strategies may have a positive effect on the quality of life, mental conditions and treatment of patients with depression.Disclosure of interestThe authors have not supplied their declaration of competing interest.
31
Bran, M., M. Ladea, D. Stanculescu y T. Purnichi. "Psychiatric comorbidities in patients with brain tumors after radiotherapy – An intermediate report". European Psychiatry 33, S1 (marzo de 2016): S204. http://dx.doi.org/10.1016/j.eurpsy.2016.01.487.
Texto completoResumen
IntroductionPrimary or secondary CNS tumors are among the most difficult to manage forms of cancer. Treatment of these tumors remains a challenge in oncology and the success rates for treatment of brain tumors are much lower than in extracerebral localizations. Because most chemotherapeutic agents do not cross the blood-brain barrier effectively and surgery is sometimes only palliative, radiotherapy remains the main method of treatment of these lesions. Both localized and generalized brain radiotherapy have numerous psychiatric complications.ObjectivesThe objective of the study was to assess the psychiatric comorbidities in patients with brain tumors receiving radiotherapy.AimsThis is an intermediate report of a larger study that assesses comorbidities in patients with brain tumors after radiotherapy.MethodsTwenty-five patients with different localization brain tumors were included in this observational study before receiving radiotherapy. All patients were assessed using Hospital Anxiety and Depression Scale (HADS) for anxiety and depressive symptoms, Montreal Cognitive Assessment (MOCA) for cognitive impairment and Quality of Life Enjoyment and Satisfaction Questionnaire–Short Form (Q-LES-Q-SF) at inclusion and after 3 months from finishing the radiotherapy sessions.ResultsTwenty-two patients completed the study. Nine patients received antidepressant treatment (sertraline, tianeptine) during the study for depressive symptoms or anxiety. Patients receiving antidepressants showed better scores on HADS, MOCA and Q-LES-Q-SF scales.ConclusionsAntidepressant use in patients receiving radiotherapy for brain tumors could be neuroprotective and could improve quality of life.Disclosure of interestThe authors have not supplied their declaration of competing interest.
32
Yeung, Albert, Lauren E. Slipp, Jolene Jacquart, Maurizio Fava, John W. Denninger, Herbert Benson y Gregory L. Fricchione. "The Treatment of Depressed Chinese Americans Using Qigong in a Health Care Setting: A Pilot Study". Evidence-Based Complementary and Alternative Medicine 2013 (2013): 1–5. http://dx.doi.org/10.1155/2013/168784.
Texto completoResumen
Background. This pilot study examined the feasibility and efficacy of providing Qigong treatment in a health center to Chinese Americans with major depressive disorder (MDD).Methods. Fourteen Chinese Americans with MDD were enrolled, and they received a 12-week Qigong intervention. The key outcome measurement was the 17-item Hamilton Rating Scale for Depression (HAM-D17); the Clinical Global Impressions-Severity (CGI-S) and -Improvement (CGI-I), the Quality of Life Enjoyment and Satisfaction Questionnaire, Short Form (Q-LES-Q-SF), and the Multidimensional Scale of Perceived Social Support (MSPSS) were also administered. Positive response was defined as a decrease of 50% or more on the HAM-D17, and remission was defined as HAM-D17≤ 7. Patients' outcome measurements were compared before and after the Qigong intervention.Results. Participants (N=14) were 64% female, with a mean age of 53 (±14). A 71% of participants completed the intervention. The Qigong intervention resulted in a positive treatment-response rate of 60% and a remission rate of 40% and statistically significant improvement, as measured by the HAM-D17, CGI-S, CGI-I, Q-LES-Q-SF, and the family support subscale of the MSPSS.Conclusions. The Qigong intervention provided at a health care setting for the treatment of primary care patients with MDD is feasible. Further studies with larger sample sizes are warranted.
33
Mychaskiw, M. A., J. M. Alvir, B. K. Herman, S. Pallanti y A. Joshi. "Insomnia and Quality of Life in Generalized Anxiety Disorder: Impact on Clinical Presentation and Response to Pregabalin and Venlafaxine-XR". European Psychiatry 24, S1 (enero de 2009): 1. http://dx.doi.org/10.1016/s0924-9338(09)70767-9.
Texto completoResumen
Aims:To assess the impact of insomnia on quality of life (QoL) and functioning in patients with generalized anxiety disorder (GAD), and evaluate the efficacy of pregabalin and venlafaxine-XR in improving sleep and QoL.Methods:A double-blind trial in adults who met DSM-IV criteria for GAD, with a HAM-A total score ≥20,randomized to 8-weeks of flexible-dose treatment with pregabalin (300-600 mg/d, N=121), venlafaxine-XR (75-225 mg/d, N=125), or placebo (N=128).Results:At baseline, 64% of all subjects had insomnia (according to the Medical Outcomes Study Sleep scale [MOS]-Sleep Problems Index [SPI] criteria).While HAM-A total scores (minus the insomnia item) were similar for patients with and without baseline insomnia (25.7 vs. 25.0) those with reported significantly more impairment on the Quality of Life, Enjoyment, and Satisfaction Questionnaire (Q-LES-Q; 45.4 vs. 53.6; p< 0.0001) and Sheehan Disability Scale (SDS; 17.5 vs.14.3; p< 0.0001) than those without. At endpoint, there was a significantly greater mean improvement in MOS-sleep disturbance factor and MOS-SPI with pregabalin (-29.0 and -21.1, respectively) than venlafaxine-XR (-14.7 and -11.0) or placebo (-15.2 and -12.5; all p< 0.05). In more pregabalin (64%) than venlafaxine-XR (51%) or placebo (52%) subjects, abnormal baseline sleep had normalized by endpoint. Endpoint change in MOS-SPI significantly correlated with improvement in both Q-LES-Q and SDS-total scores (Spearman r-values, -0.48 and 0.46, respectively; both p< 0.0001; all subjects).Conclusion:Significantly greater impairment in QoL and functioning was observed in patients with high (vs. low) levels of insomnia. Pregabalin produced significantly greater improvement in insomnia than venlafaxine-XR or placebo.
34
He, J. Allison, Kevin M. Antshel, Joseph Biederman y Stephen V. Faraone. "Do Personality Traits Predict Functional Impairment and Quality of Life in Adult ADHD? A Controlled Study". Journal of Attention Disorders 23, n.º 1 (25 de noviembre de 2015): 12–21. http://dx.doi.org/10.1177/1087054715613440.
Texto completoResumen
Objective: To examine the association of personality traits and characteristics on quality of life and functioning in adults with ADHD. Method: Participants were adults with ( n = 206) and without ADHD ( n = 123) who completed the Temperament and Character Inventory (TCI), the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q), and the Social Adjustment Scale–Self-Report (SAS-SR). Participants also provided information on academic, motor vehicle operation, legal, social, familial, and occupational functioning. Outcomes were examined using stepwise linear regression, logistic regression (for binary outcomes), and negative binomial regression (for count outcomes) controlling for ADHD symptoms, psychiatric comorbidity, and executive dysfunction. Results: Adults with ADHD significantly differed from controls across nearly all TCI personality domains. On average, adults with ADHD endorsed more novelty seeking, harm avoidance, and self-transcendence, and less reward dependence, persistence, self-directedness, and cooperativeness. Personality traits and characteristics, especially self-directedness, significantly predicted functional impairments even after controlling for ADHD symptoms, executive function deficits, and current psychiatric comorbidities. Conclusion: In adults with ADHD, personality traits exert unique associations on quality of life and functional impairment across major life domains, beyond the relations expected of and associated with ADHD symptoms and other associated psychiatric conditions and cognitive vulnerabilities. Addressing personality traits in adults with ADHD may lead to improvements in quality of life and reductions in functional impairment.
35
Ilievová, Ľubica, Peter Žitný y Jana Jakobejova. "The association between the quality of life and depression of elderly in a nursing home institutional setting". Journal of Health Sciences 6, n.º 3 (20 de diciembre de 2016): 162–67. http://dx.doi.org/10.17532/jhsci.2016.364.
Texto completoResumen
Introduction: The quality of life is perceived individually and subjectively. The quality of life of elderly people in nursing home nursing homes depends on the degree to which their needs are fulfilled. The need to adapt to a new environment in an older age is a risky situation and may result in depression. The aim of the study was to analyze the change of quality of life and level of depression, as well as possible association of quality of life and level of depression, in elderly people admitted for the first time to nursing home.Methods: The research included 38 participants (10 men and 28 women). The data were obtained using the Geriatric Depression Rating Scale Short Form (GDS-SF) and a short form of the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q-SF).Results: The average age was 79.2 (SD = 6.9) with a variation span of 30 years, minimum age was 62 (n = 1) and maximum age was 92 years (n = 1).The participants experienced a clinically significant reduction in depression symptoms, moving from a mild depression zone (8-12 points) to the zone of clinical standard (7 points or less). An essential finding was a strong negative correlation between the quality of life and depression.Conclusions: Obtaining information on depression and the quality of life of elderly in nursing home settings should be introduced as a standard part of nursing activities in order to improve the quality of customer care in the nursing homes.
36
Faber, Jessie y Eunjung Lee. "Cognitive-Behavioral Therapy for a Refugee Mother With Depression and Anxiety". Clinical Case Studies 19, n.º 4 (31 de mayo de 2020): 239–57. http://dx.doi.org/10.1177/1534650120924128.
Texto completoResumen
This case study illustrates a short-term cognitive behavioral therapy (CBT) for a refugee single mother of a 4-year-old son to address depression and anxiety symptoms. Although she has histories of multiple trauma experiences such as sexual abuse and intimate partner violence, the client preferred to focus on current difficulties rather than trauma histories. As such, non-trauma-focused CBT utilizing psychoeducation, skill building, activity monitoring and scheduling, and cognitive restructuring is implemented over 10 individual sessions. The client’s progress was measured by the Depression Anxiety Stress Scale (DASS-21), the Quality of Life Enjoyment and Satisfaction Questionnaire–Short Form (Q-LES-Q-SF), and a full-length Columbia-Suicide Severity Rating Scale (C-SSRS) at the intake, midpoint, and last session. The client showed improvement in all measures after the treatment, which corresponded with the client’s verbal reports during the session. This case illustrates the critical clinical decision-making points made by the therapist, and recommends the evidence-based practice protocol that considers empirically supported treatments for the comorbidity of depression and anxiety with multiple trauma experiences, the client preference, and contextual factors in addressing complex clinical presentations.
37
Nasrallah, Henry, David Walling, Peter J. Weiden, Yangchun Du, Baiyun Yao, Sergey Yagoda y Amy Claxton. "Aripiprazole Lauroxil 2-Month Formulation With 1-Day Initiation for Acute Schizophrenia: ALPINE Exploratory Efficacy and Patient-Reported Outcomes". CNS Spectrums 26, n.º 2 (abril de 2021): 171–72. http://dx.doi.org/10.1017/s1092852920002795.
Texto completoResumen
AbstractObjectiveThe randomized, controlled, phase 3b ALPINE study evaluated efficacy and safety of a 2-month formulation of aripiprazole lauroxil (AL) initiated with a 1-day regimen during hospitalization for an acute exacerbation of schizophrenia; paliperidone palmitate (PP) was included as an active control. The primary efficacy outcome, within-group change from baseline in PANSS total score at 4 weeks, was previously reported. Here we report additional exploratory PANSS subscale endpoints and patient-reported outcomes (PROs).MethodsAdults aged 18–65 years were enrolled as inpatients and randomized to AL 1064 mg q8wk or PP 156 mg q4wk and discharged after 2 weeks of study treatment if clinically stable. Patients were followed as outpatients through week 25. Exploratory efficacy endpoints were PANSS subscale (Positive, Negative, and General) and Clinical Global Impression-Severity (CGI-S) scores. The Burden Assessment Scale was administered to patients’ nonprofessional caregivers (family member or friend). Exploratory PROs (Quality of Life Enjoyment and Satisfaction Questionnaire Short Form [Q-LES-Q-SF] and Medication Satisfaction Questionnaire) were assessed during the outpatient period. Within-group changes in PANSS subscales and CGI-S scores from baseline through week 25 were analyzed for AL and PP using mixed models with repeated measures. PROs were summarized based on observed data.ResultsIn total, 200 patients were randomized (AL, n=99; PP, n=101); 99 (AL, n=56; PP, n=43) completed the 25-week study. PANSS Positive, Negative, and General subscale scores improved with AL treatment as measured by change from baseline to week 25 (least squares [LS] mean [95% CI]: Positive, −7.0 [−8.1, −6.0]; Negative, −3.7 [−4.7, −2.8]; General, −11.1 [−12.7, −9.5]), as did CGI-S scores (LS mean [95% CI] change at week 25: –1.2 [–1.4 –1.0]). Caregiver burden decreased over the treatment period, with the largest decline noted at week 9 for AL patients’ caregivers (mean change from baseline at week 9: −8.4; week 25: −8.9). Over weeks 5, 9, and 17, 70.8%−74.7% of AL-treated patients were somewhat or very satisfied with treatment. Mean Q-LES-Q-SF total scores were stable. With PP, PANSS subscale and CGI-S scores improved from baseline to study end (LS mean [95% CI] changes at week 25: Positive, −7.1 [−8.2, −5.9]; Negative, −3.5 [−4.6, −2.5]; General, −10.4 [−12.1, −8.6]; CGI-S, −1.2 [−1.5, −1.0]). Mean caregiver burden decreased (week 9: −8.8; week 25: −9.2). Most PP patients were satisfied or very satisfied with treatment (64.7%−69.3% at weeks 5, 9, and 17), and mean Q-LES-Q-SF total scores were stable.ConclusionIn ALPINE, patients who initiated AL or PP in the hospital and continued treatment during outpatient care experienced improvement in schizophrenia symptoms and reported satisfaction with medication, decreased caregiver burden, and stable quality of life.FundingAlkermes, Inc.
38
Holubova, M., J. Prasko, K. Latalova, M. Ociskova, A. Grambal, D. Kamaradova, K. Vrbova y R. Hruby. "Self-stigma and quality of life in Psychopharmacs treated outpatients with schizophrenia and related disorders - A cross-sectional study". European Psychiatry 33, S1 (marzo de 2016): s253—s254. http://dx.doi.org/10.1016/j.eurpsy.2016.01.642.
Texto completoResumen
IntroductionSelf-stigma is a maladaptive psychosocial phenomenon that can disturb self-image and quality of life in psychiatric outpatients and may lead to dysphoria, social isolation and reduced adherence to treatment.ObjectivesSelf-stigma and QoL could be reflected as important factors for patients, who suffer from schizophrenia spectrum disorders, their caregivers and mental health specialists. Focus on reducing the self-stigma in supportive and educational therapy could be an important factor in promoting a higher QoL.AimsCurrent research moved attention to the relationship between demographic data, the severity of symptoms, self-stigma and quality of life in schizophrenic outpatients compared to the QoL in healthy controls.MethodsPatients who met ICD-10 criteria for schizophrenia spectrum disorder were recruited in the study. The Quality of Life Satisfaction and Enjoyment questionnaire (Q-LES-Q), Internalized Stigma of Mental Illness (ISMI) and severity of the disorder measured by objective and subjective Clinical Global Impression severity scales (CGI) were assessed.ResultsOne hundred and nine psychotic patients and 91 healthy controls participated in the study. Compared to the control group, there was a lower QoL and a higher score of self-stigma in psychotic patients. We found the correlation between the self-stigma, duration of disorder and QoL. The level of self-stigma correlated positively with total symptom severity score and negatively with the QoL. Stepwise regression analysis revealed that the objective severity and self-stigma score were significantly associated with the quality of life (Figure 2 and 3, Fig. 1).ConclusionsOur study suggests a negative impact of self-stigma level on the quality of life in patients suffering from schizophrenia spectrum disorders.Disclosure of interestThe authors have not supplied their declaration of competing interest.
39
Weiss, Catherine, Stine Rasmussen Meehan, William R. Lenderking, Huda Shalhoub, Carla Dias-Barbosa, Andrea Schulz, Justin Chen y Malik Greene. "T220. IMPACT OF SECOND-GENERATION ANTIPSYCHOTIC SIDE EFFECTS ON FUNCTIONING FROM A SCHIZOPHRENIA PATIENT PERSPECTIVE: GLOBAL PATIENT CENTERED SURVEY INCLUDING PATIENTS FROM ITALY". Schizophrenia Bulletin 46, Supplement_1 (abril de 2020): S316—S317. http://dx.doi.org/10.1093/schbul/sbaa029.780.
Texto completoResumen
Abstract Background Second-generation antipsychotics (SGAs) used to treat patients with schizophrenia generally have lower risk of motor side effects (SEs) than first-generation antipsychotics, but they are associated with other well-known SEs. The goal of this study was to understand how specific SEs of SGAs impact daily functioning, emotional well-being, and overall quality of life of patients with schizophrenia from their own perspective. Methods This study was a cross-sectional, participant-reported web survey, conducted globally during 2017–2018. The survey captured participants’ socio-demographic information, and assessments using the Quality of Life Enjoyment and Satisfaction Questionnaire Short Form (Q-LES-Q-SF) instrument, and the Glasgow Antipsychotic Side-Effect Scale (GASS). Additionally, specific questions about functional and emotional impacts were developed for SEs recognized as being bothersome to patients,2 such as activating SEs (‘Feeling restless/unable to sit still’, ‘Shaky hands or arms’, and ‘Difficulty sleeping’) sedating SEs (‘Feeling sleepy during the day’, ‘Feeling drugged/like a zombie’) and metabolic or endocrine SEs (‘Weight gain’, ‘Problems enjoying sex’). Participants noted on a visual analog scale (VAS) the degree of impact on functioning, 0 indicating ‘no impact at all’ and 100 indicating the ‘largest degree of impact’. Participants with schizophrenia (≥18 years old) stable for at least one month, taking an SGA for 1–12 months, and self-reporting at least one SE were included. Results Of 6,556 respondents screened, 435 were included in the study – United States, n=180; Canada, n=99; Australia, n=28; and Europe, n=128 (Italy, n=90; Spain, n=22; Denmark, n=8; Norway, n=8). The majority of the participants were diagnosed within the last 5 years and nearly half were living with a spouse or partner. The employment rate (full time or part time) was 39.9% globally and 43.3% in Italy. Respondents in Italy were on ‘predominantly sedating’ (54.4%), and/or ‘similarly activating and sedating’ (43.3%) SGAs (as defined in Citrome, J Clin Psychopharmacol 2017). In Italy, Q-LES-Q-SF total score was (mean [standard deviation; SD]) 46.6 [9.1], out of a possible score range of 14–70 (globally, 44.3 [9.8]). Similar to other countries, participants from Italy showed lowest satisfaction scores for Q-LES-Q-SF items of ‘Sexual drive, interest and/or performance’, ‘Economic status’, and ‘Work’. In Italy, the most prevalent SEs reported on the GASS were ‘Feeling sleepy during the day’, ‘Difficulty sleeping’, and ‘Problems enjoying sex’, while globally patients reported ‘Feeling sleepy during the day’, ‘Difficulty sleeping’, and ‘Dry mouth’ as the most common SEs. More than half of the participants stated they had experienced gaining weight as an SE (52.4% globally and 62.2% in Italy). Globally, SEs perceived as bothersome by patients were reported to impact participants’ functioning and emotions. These SEs had at least a moderate to severe impact (defined by a VAS score ≥50) on all aspects of functioning (physical, psychological, social, and vocational). The most common emotions associated with SEs reported by participants were feeling ‘Frustrated’, ‘Dissatisfied’, and ‘Ashamed/embarrassed’. Generally, the results from the survey in Italy were comparable to those of the global survey. Discussion Findings from this survey confirm that participants taking SGAs for the treatment of schizophrenia still have many SEs, including activating and sedating SEs, sexual SEs, and weight gain. These SEs have a considerable negative impact on participant’s daily functioning and quality of life satisfaction, including on work, and sexual drive, in addition to psychosocial effects.
40
Bourion-Bédès, Stéphanie, Raymund Schwan, Jonathan Epstein, Vincent Laprevote, Alex Bédès, Jean-Louis Bonnet y Cédric Baumann. "Combination of classical test theory (CTT) and item response theory (IRT) analysis to study the psychometric properties of the French version of the Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form (Q-LES-Q-SF)". Quality of Life Research 24, n.º 2 (12 de agosto de 2014): 287–93. http://dx.doi.org/10.1007/s11136-014-0772-y.
Texto completo
41
Findling, R., R. Goldman, J. Cucchiaro, L. Deng y A. Loebel. "The Efficacy and Safety of Lurasidone in Adolescent Patients with Schizophrenia: Results of Functional and Quality of Life Measures from a 6-week, Double-blind, Placebo-controlled Study". European Psychiatry 41, S1 (abril de 2017): S94. http://dx.doi.org/10.1016/j.eurpsy.2017.01.292.
Texto completoResumen
IntroductionLurasidone, an atypical antipsychotic, demonstrated efficacy and safety in adults with schizophrenia.Objective/AimsTo evaluate the efficacy and safety of lurasidone in adolescent patients with schizophrenia.MethodsAdolescents (13–17 years old) with schizophrenia were randomly assigned to six weeks of double-blind treatment with lurasidone 37 mg/day, 74 mg/day or placebo. An ANCOVA using an LOCF approach was performed to assess change from baseline on secondary study endpoints: Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q) and Children's Global Assessment Scale (CGAS).ResultsPatients were randomized to lurasidone 37 mg/d (n = 108), 74 mg/day (n = 106), or placebo (n = 112). Placebo-adjusted LS mean improvement at week 6 on the PQ-LES-Q was 5.3 (P = 0.001) and 5.8 (P < 0.001) for the 37 mg/day and 74 mg/day groups, respectively; and, on the CGAS was 4.6 (P = 0.002) and 4.9 (P < 0.001) for the 37 mg/day and 74 mg/d groups, respectively. The most common adverse events occurring at ≥ 5% in either lurasidone group and at least twice the rate of placebo were: nausea, somnolence, akathisia, vomiting and sedation. Mean change in weight at week 6 for placebo, 37 mg/day, and 74 mg/day groups was 0.05 kg, 0.17 kg, and 0.49 kg, respectively. Lurasidone treated patients did not show clinically meaningful differences from placebo on laboratory measures of cholesterol, triglycerides, glucose, and prolactin.ConclusionsAdolescent patients with schizophrenia treated with lurasidone demonstrated significant improvement in quality of life and function. Lurasidone was generally well-tolerated and associated with minimal changes in weight and metabolic parameters. Sponsored by Sunovion Pharmaceuticals Inc. ClinicalTrials.gov identifier: NCT01911429.Disclosure of interestDr. Findling receives or has received research support, acted as a consultant and/or served on a speaker's bureau for Alcobra, American Academy of Child & Adolescent Psychiatry, American Physician Institute, American Psychiatric Press, Bracket, CogCubed, Cognition Group, Coronado Biosciences, Dana Foundation, Elsevier, Forest, Guilford Press, Ironshore, Johns Hopkins University Press, Jubilant Clinsys, KemPharm, Lundbeck, Merck, NIH, Neurim, Novartis, Otsuka, Oxford University Press, Pfizer, Physicians Postgraduate Press, Purdue, Rhodes Pharmaceuticals, Roche, Sage, Shire, Sunovion, Supernus Pharmaceuticals, Transcept Pharmaceuticals, Tris, Validus, and WebMD. Drs. Goldman, Cucchiaro, Deng, and Loebel are employees of Sunovion Pharmaceuticals Inc.
42
Perikova, Ekaterina I., Inna V. Atamanova, Sergey A. Bogomaz, Baizhol I. Karipbayev, Tatyana S. Filippova y Diana Zagulova. "The Relationship Between Value Orientations and Personal Readiness for Activity in Youth From Russia, Kazakhstan and Latvia". Psychology in Russia: State of the Art 14, n.º 2 (2021): 118–36. http://dx.doi.org/10.11621/pir.2021.0208.
Texto completoResumen
Background. The development of high-quality human capital is an important objective that involves value orientations, cultural dimensions and psychological characteristics of activity. This article presents a cross-cultural comparison of value orientations and psychological parameters of activity among youth from Russia, Kazakhstan, and Latvia. Objective. The study addressed three questions: (1) Are there values and attitudes related to the readiness for activity among youth in the three countries? (2) Are there any differences between values and parameters of the psychological system of activity in the Russian, Kazakhstani and Latvian samples? (3) What values and attitudes predict the youth’s readiness for activity in each country? Design. University students from Russia, Kazakhstan and Latvia were invited to participate in the study. The study sample was selected according to age, sex and period of living in the country. Value orientations, cultural dimensions and attitudes were measured by the VSM, WVS, Basic Values Realisability questionnaires. The PRF, Q-LES-Q, SHS, Self-Organization of Activity, DTR, and SWLS questionnaires were applied to evaluate the psychological parameters of activity. To analyse the relationship between value orientations and psychological parameters of activity, we used analysis of variance, Pearson's correlation coefficient and stepwise linear regression. Results. The cross-cultural variance was established for most values and cultural dimensions in the Russian, Kazakhstani, and Latvian samples, but Personal readiness for activity only differed on the tendency level between the Kazakhstani and Latvian samples. Different values and attitudes accounted for near 57% of the Personal readiness for activity index in Russia and Latvia, but just less than 29% in Kazakhstan. Conclusion. The activity of university students from Russia depends on their need for achievement and level of happiness. In the Kazakhstani and Latvian samples, the most important factor was the quality of life enjoyment and satisfaction index
43
Carmassi, Claudia, Francesco Pardini, Valerio Dell’Oste, Annalisa Cordone, Virginia Pedrinelli, Marly Simoncini y Liliana Dell’Osso. "Suicidality and Illness Course Worsening in a Male Patient with Bipolar Disorder during Tamoxifen Treatment for ER+/HER2+ Breast Cancer". Case Reports in Psychiatry 2021 (24 de marzo de 2021): 1–7. http://dx.doi.org/10.1155/2021/5547649.
Texto completoResumen
Purpose. Tamoxifen is a selective estrogenic receptor modulator (SERM) drug. In addition to its common use in breast cancer ER+, Tamoxifen has been object of growing interest in psychiatry as antimanic drug. At the same time, clinical concerns about Tamoxifen’s depressogenic effect have been repeatedly raised even without reaching univocal conclusions. We discuss the case of a 45-year-old-male with a diagnosis of Bipolar Disorder type II, treated with Tamoxifen as relapse prevention treatment after surgery for a ER+/HER2+ breast cancer. The patient required two psychiatric admissions in a few-month time span since he showed a progressive worsening of both depressive and anxiety symptoms, with the onset of delusional ideas of hopelessness and failure up to suicidal thoughts. The clinical picture showed poor response to treatment trials based on various associations of mood-stabilising, antidepressants, and antipsychotic drugs. During the second hospitalization, after a multidisciplinary evaluation, the oncologists agreed on Tamoxifen discontinuation upon the severity of the psychiatric condition. The patient underwent a close oncological and psychiatric follow-up during the following 12 months. Methods. Psychiatric assessments included the Montgomery-Asberg Depression Rating Scale (MADRS), the Hamilton Depression Scale (HAM-D), the Columbia Suicide Severity Rating Scale (C-SSRS), and the Quality of Life Enjoyment and Satisfaction Questionnaire Short Form (Q-LES-Q-SF). All questionnaires were administered at the time of the second hospitalization and in a one-year follow-up. Results. Suicidal ideation fully remitted and depressive symptoms markedly and rapidly improved in the aftermath of Tamoxifen discontinuation. The symptomatological improvement remained stable across one-year follow-up. Conclusions. Male patients with a mood disorder history constitute a high-risk group as to Tamoxifen psychiatric side effects. The onset or worsening of depressive symptoms or suicidality should be carefully addressed and promptly treated, and clinicians should be encouraged to consider the possibility of discontinue or reduce Tamoxifen therapy after a multidisciplinary evaluation.
44
Morton, Emma, Erin E. Michalak, Anthony Levitt, Robert D. Levitan, Amy Cheung, Rachel Morehouse, Rajamannar Ramasubbu, Lakshmi N. Yatham, Edwin M. Tam y Raymond W. Lam. "Quality of Life Impacts of Bright Light Treatment, Fluoxetine, and the Combination in Patients with Nonseasonal Major Depressive Disorder: A Randomized Clinical Trial". Canadian Journal of Psychiatry, 23 de junio de 2020, 070674372093647. http://dx.doi.org/10.1177/0706743720936470.
Texto completoResumen
Objective: Bright light therapy is increasingly recommended (alone or in combination with antidepressant medication) to treat symptoms of nonseasonal major depressive disorder (MDD). However, little is known about its impacts on quality of life (QoL), a holistic, patient-valued outcome. Methods: This study utilizes secondary outcome data from an 8-week randomized, controlled, double blind trial comparing light monotherapy ( n = 32), fluoxetine monotherapy ( n = 30), and the combination of these ( n = 27) to placebo ( n = 30). QoL was assessed using the Quality of Life Enjoyment and Satisfaction Questionnaire Short Form (Q-LES-Q-SF). Treatment-related differences in QoL improvements were assessed using a repeated measures analysis of variance. The influence of potential predictors of QoL (demographic variables and change in depressive symptoms) were investigated via hierarchical linear regression. Results: Q-LES-Q-SF scores significantly improved across all treatment conditions; however, no significant differences were observed between treatment arms. QoL remained poor relative to community norms by the end of the trial period: Across conditions, 70.6% of participants had significantly impaired QoL at the 8-week assessment. Reduction in depressive scores was a significant predictor of improved QoL, with the final model accounting for 54% of variance in QoL change scores. Conclusion: The findings of this study emphasize that improvement in QoL and reduction in depressive symptoms in MDD, while related, cannot be taken to be synonymous. Adjunctive therapies may be required to address unmet QoL needs in patients with MDD receiving antidepressant or light therapies. Further research is required to explore additional predictors of QoL in order to better refine treatments for MDD.
45
Luo, Zeng-Rong, Dong-Shan Liao y Liang-Wan Chen. "Comparative analysis of postoperative sexual dysfunction and quality of life in type a aortic dissection patients of different ages". Journal of Cardiothoracic Surgery 16, n.º 1 (1 de mayo de 2021). http://dx.doi.org/10.1186/s13019-021-01468-0.
Texto completoResumen
Abstract Background To compare postoperative sexual dysfunction (SD) and quality of life (QOL) in Type A Aortic Dissection (AAD) Patients of Different Ages. Methods From January 2018 to December 2019, 204 AAD postoperative survivors in Union Hospital of Fujian Medical University were selected and were divided into young group (less than 50 years old) and elderly group (more than 50 years old). We evaluated SD according to the male International Erectile Dysfunction Index (IIEF-5) and female sexual function index (FSFI). The Short Form 12 Health Survey Questionnaire (SF-12) and Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) were used to investigate the QOL, Quick Inventory Depressive Symptomatology-Self Report (QIDS-SR) and the Beck Depression Inventory-II (BDI-II) to investigate depressive symptoms. Results One hundred seventy-five patients completed all the questionnaire (85.8%). The total SD prevalence rate was 38.9% (68 cases), with 27.4% of the young (20 cases) and 47.1% of the elderly (48 cases). The age of non-SD and SD patients was 49.0 ± 11.5 and 56.9 ± 10.8 years, respectively (P = 0.03). Compared with non-SD patients, the total physical health of SD patients was significantly worse (P = 0.04), however, the mental health was not significantly worse (P = 0.77); the depressive symptoms did not expressed a significant difference between the SD and non-SD groups (QIDS-SR P = 0.15, BDI-II P = 0.06). Total physical health scores in the young SD group did not show significant better than elderly SD group (P = 0.24), however, total mental health scores showed significantly worse (P = 0.04), depressive symptoms scores were significantly higher (QIDS-SR P = 0.03, BDI-II P = 0.04). Conclusion The postoperative AAD SD prevalence of elderly is higher than that of young, and the total physical health of SD patients is poorer than those without SD patients. The young SD patients did not show a significant higher physical health scores than the elderly SD patients, instead, the young SD patients were more psychologically affected than the elderly SD patients, whose mental health was worse, and depression symptoms were more obvious, suggesting that the factors affecting the QOL of postoperative SD patients are related to physical factors, but the young postoperative SD patients mainly affected by psychological factors.